CKAP2L Antibody

What is CKAP2L and how does it differ from CKAP2?

CKAP2L (Cytoskeleton-associated protein 2-like protein), also known as Radmis (Radial fiber and mitotic spindle protein), is a microtubule-associated protein essential for mitotic spindle formation and cell-cycle progression in neural progenitor cells . While CKAP2L and CKAP2 (also known as LB1, TMAP, or Cytoskeleton-associated protein 2) are related, they have distinct functions. CKAP2 possesses microtubule stabilizing properties and is involved in regulating aneuploidy, cell cycling, and cell death in a p53/TP53-dependent manner . When designing experiments targeting either protein, researchers must carefully select antibodies with proven specificity to avoid cross-reactivity issues between these structurally similar proteins.

What experimental applications are CKAP2L antibodies suitable for?

Commercial CKAP2L antibodies have been validated for several common laboratory techniques. According to available product information, rabbit polyclonal antibodies against CKAP2L are suitable for Western Blot (WB) and Immunocytochemistry/Immunofluorescence (ICC/IF) applications, particularly with human samples . Similarly, CKAP2/LB1 antibodies have been validated for comparable applications . When selecting an antibody for your research, consider the specific epitope targeted and whether the antibody has been cited in published research, as this provides evidence of reliability in scientific applications.

How is CKAP2L expression typically detected in tissue samples?

CKAP2L expression can be analyzed at both RNA and protein levels using complementary techniques:

• RNA level detection: RT-PCR is commonly employed to quantify CKAP2L mRNA expression in tissue samples .

• Protein level detection: Western blotting and immunohistochemistry (IHC) are standard methods for analyzing CKAP2L protein expression .

For IHC, tissues are typically embedded in paraffin, sectioned at 4-μm thickness, and stained following standard immunohistochemical protocols. For optimal results and reliability, analysis should be performed by experienced pathologists, preferably using a dual-headed microscope for consensus evaluation .

What controls should be included when working with CKAP2L antibodies?

When designing experiments with CKAP2L antibodies, proper controls are essential for result validation. Include positive control samples with known CKAP2L expression, such as certain cancer tissues or cell lines documented to express CKAP2L. For Western blotting, GAPDH is commonly used as a loading control (ab8245, Abcam has been documented for this purpose) . For protein extraction, use radioimmunoprecipitation assay (RIPA) buffer with protease inhibitor mixture, and measure protein concentration via bicinchoninic acid (BCA) assay before proceeding with SDS-PAGE gel electrophoresis . Always include appropriate negative controls and consider antibody validation through techniques such as siRNA knockdown or CRISPR knockout of CKAP2L.

How does CKAP2L expression correlate with clinical outcomes in cancer research?

Research on clear cell renal cell carcinoma (ccRCC) has demonstrated that CKAP2L is significantly upregulated in tumor tissues compared to normal tissues. Analysis of multiple datasets including TCGA, GSE76351, GSE53757, and GSE66270 consistently shows higher CKAP2L expression in tumor samples . This elevated expression correlates with several crucial clinical characteristics:

• Tumor stage

• TNM classification

• Patient prognosis

Survival analysis and Cox regression analysis indicate that CKAP2L is an independent prognostic factor in ccRCC patients, with higher expression correlating with poorer outcomes . This suggests CKAP2L's potential as both a prognostic biomarker and a therapeutic target. When investigating CKAP2L in cancer samples, researchers should correlate expression levels with comprehensive clinical data to establish meaningful clinical associations.

What signaling pathways are associated with CKAP2L function in cancer progression?

Gene enrichment analyses, including Gene Set Enrichment Analysis (GSEA) and Gene Set Variation Analysis (GSVA), have identified several critical signaling pathways associated with CKAP2L in cancer progression:

• JAK-STAT signaling pathway

• P53 signaling pathway

• TGF-β signaling pathway

Additionally, protein-protein interaction analysis and co-expression analysis suggest that CKAP2L affects cell cycle regulation and cellular division in cancer cells . When investigating CKAP2L's role in cancer, researchers should design experiments that can monitor these pathways, potentially using phospho-specific antibodies or reporter systems that can detect pathway activation states following CKAP2L modulation.

What is the relationship between CKAP2L and tumor immune microenvironment?

CKAP2L expression shows significant correlations with specific immune cell infiltration patterns in the tumor microenvironment. In ccRCC, CKAP2L is positively correlated with numerous inhibitory immune checkpoint genes, suggesting indirect influence on immune system functions . Immune cell analysis using CIBERSORT revealed:

• Positive correlations with CD8+ T cells, naïve CD4+ T cells, activated memory CD4+ T cells, Tregs, activated NK cells, M0 macrophages, M1 macrophages, and neutrophils

• Negative correlations with naïve B cells, plasma cells, resting NK cells, monocytes, activated dendritic cells, and resting mast cells

When studying CKAP2L in cancer contexts, researchers should consider analyzing immune cell infiltration patterns through immunohistochemistry or flow cytometry to validate computational predictions. Preliminary IHC validations have shown higher M1 macrophage infiltration in CKAP2L-high ccRCC tissues, though the relationship with CD4+ T cells remains inconclusive .

How can researchers address heterogeneity in CKAP2L studies across different cancer types?

While CKAP2L upregulation has been documented in multiple cancer types (glioma, breast cancer, ovarian cancer, and ccRCC), the specific mechanisms and effects may vary between cancers . To address this heterogeneity:

• Employ tissue-specific experimental designs with appropriate controls

• Consider cancer-specific molecular contexts when interpreting results

• Validate findings across multiple patient cohorts

• Use both in silico analysis and experimental validation

• Account for differences in immune microenvironments across cancer types

Researchers should acknowledge that CKAP2L may exert different functions in different tissue contexts and immune microenvironments, necessitating cancer-specific investigations rather than generalizing findings across all cancer types.

What are the optimal protocols for Western blotting with CKAP2L antibodies?

For optimal Western blotting results with CKAP2L antibodies, follow these methodological considerations:

• Protein extraction: Collect tissues in RIPA buffer supplemented with protease inhibitor mixture

• Protein quantification: Measure concentration using BCA assay

• SDS-PAGE: Load equal amounts of protein into each well

• Transfer: Transfer proteins onto PVDF membrane (Millipore, Billerica, MA has been validated)

• Primary antibody: Incubate with anti-CKAP2L antibody (e.g., NBP1-83450, Novus Biologicals)

• Loading control: Use anti-GAPDH antibody (ab8245, Abcam) as internal control

• Secondary antibody: Apply horseradish peroxidase-conjugated secondary antibody

• Visualization: Use standard chemical luminescence method

Optimization of antibody concentration and incubation times may be necessary depending on sample type and protein abundance.

What considerations should be made when performing immunohistochemistry with CKAP2L antibodies?

For successful immunohistochemical detection of CKAP2L in tissue samples:

• Sample preparation: Embed tissue in paraffin and cut into 4-μm sections

• Protocol adherence: Follow standard immunohistochemical staining protocol

• Analysis: Have at least two expert pathologists analyze results independently

• Consensus evaluation: Use a dual-headed microscope for collaborative analysis when evaluating difficult cases

• Controls: Include positive and negative control tissues in each staining batch

• Co-staining: Consider co-staining for other markers (e.g., immune cell markers like CD4 or M1 macrophage markers) when investigating microenvironment relationships

Careful optimization of antigen retrieval conditions and antibody dilutions is essential for specific staining and minimizing background.

How can researchers validate CKAP2L knockdown or overexpression experiments?

When manipulating CKAP2L expression for functional studies, proper validation is crucial:

• RNA level validation: Perform RT-PCR to confirm changes in CKAP2L mRNA expression

• Protein level validation: Use Western blotting with validated CKAP2L antibodies to confirm protein expression changes

• Functional validation: Design assays to measure expected phenotypic changes (cell cycle progression, spindle formation)

• Rescue experiments: Perform rescue experiments to confirm specificity of observed effects

• Multiple knockdown/overexpression methods: Use at least two different methods (siRNA, shRNA, CRISPR) to rule out off-target effects

These validation steps ensure that observed phenotypes are specifically attributed to CKAP2L modulation rather than technical artifacts or off-target effects.

What bioinformatic approaches are recommended for analyzing CKAP2L expression data?

For comprehensive analysis of CKAP2L in cancer research settings: